Scientific Reports · 2020 · 19 citations · 20 references
MedicineOncologyRadiation OncologyClinical Radiation OncologyMetastasisRadionuclide TherapyMetastatic Bone DiseaseMetastatic Cancer ManagementMetastatic Disease TreatmentProstate CancerRadiation TherapyTargeted Radionuclide TherapyAlpha-emitting RadiopharmaceuticalsBone Metastases ManagementBone Metastasis TherapyBone Pain PalliationCastration-resistant Prostate Cancer TherapyMetastatic Bone Disease ManagementMetastatic Castration-resistant Prostate CancerRadium Therapy
Bone is the most common site of metastasis in metastatic castration-resistant prostate cancer (mCRPC), which is associated with pain and skeletal events. Radium-223 dichloride (Xofigo) is an alpha-emitting radioactive isotope that can specifically target bone lesions. Herein, we report the results of a retrospective analysis that documents our experience in the use of radium-223. Data from 63 patients (pts) with mCRPC who underwent radium-223 treatment from December 2015 to September 2017 were collected. Radium-223 (55 kBq/kg) was administered every 4 weeks for up to 6 cycles. The primary endpoint was OS. Radium-223 was administered as first line therapy in 11 pts, as second line in 19 pts, as third line in 16 pts and in successive lines in 17 pts; 42 pts out of 63 (67%) completed all six cycles. Within one month after the end of 6 cycles of radium-223, 15 pts out of 42 (35.7%) had achieved PR, 11 pts out of 42 (26.2%) had SD and 14 pts out of 42 (33.3%) had PD. Levels of pain decreased with progressive cycles of radium-223. After a minimum follow-up of 2 months and a maximum of 43 months, median OS was 15 months and median PFS was 8 months. The most frequent radium-223 related toxicity was low grade haematologic toxicity, predominantly G1-G2, that occurred halfway through treatment in about 75% of pts. The favourable results reported herein confirm that radium-223 can be considered well tolerated and effective in mCRPC, and is associated with significant decreases in pain.
20
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations
Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 491 citations
Medicine, Oncology, Pharmacology +17